Global Nucleic Acid-based Therapy Market Outlook , 2030

2024

Global Nucleic Acid-based Therapy Market Outlook , 2030

Name: Global Nucleic Acid-based Therapy Market Outlook , 2030
Brand: Bonafide Research
SKU: 95001119
Price: 3450 USD
Availability: InStock
Rating: 4 (11.25 reviews)

The Global Lime for Iron & Steel Market is projected to surpass USD 15,900 million by 2030, driven by increasing steel production and innovations in nucleic acid therapeutics.

Bonafide Trust
09-07-2024
Pages : 121
Figures : 80
Tables : 145
Region : Global
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global nucleic acid-based therapy market has gained significant traction in recent years, primarily driven by advancements in genomics and molecular biology, as well as the increasing prevalence of genetic disorders and chronic diseases. Nucleic acid-based therapeutics, which include technologies such as RNA interference (RNAi), antisense oligonucleotides (ASOs), and gene editing techniques like CRISPR, offer targeted treatment options that can correct or modify disease-causing genes. This market has seen notable innovation, particularly in response to the COVID-19 pandemic, where nucleic acid technologies played a crucial role in developing vaccines and therapeutics. For instance, the rapid development of mRNA vaccines showcased the potential of nucleic acid-based therapies in addressing urgent health crises, leading to a surge in research and development activities globally. Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established favorable frameworks that expedite the approval processes for nucleic acid-based therapies, encouraging investment from pharmaceutical companies and biotech firms. These regulatory environments have fostered collaborations and partnerships among industry players, leading to innovative product launches and advancements in therapeutic applications. Key companies contributing to the development of the nucleic acid-based therapy market include Silence Therapeutics, Ionis Pharmaceuticals, Sarepta Therapeutics, Novartis, and Alnylam Pharmaceuticals. These companies are actively engaged in research and development, focusing on creating novel therapies for a range of conditions, including genetic disorders, cancer, and infectious diseases. For example, Novartis received FDA approval for Leqvio, a small interfering RNA therapy aimed at lowering LDL cholesterol, highlighting the commercial viability of these innovative therapies.

According to the research report "Global Lime for Iron & Steel Market Overview, 2030 " published by Bonafide Research, the Global lime for iron & steel market is projected to reach a market size of more than USD 15900 Million by 2030. The nucleic acid therapeutics market is expected to grow quickly as a result of the numerous innovative therapies that are now undergoing approval and development. The growth of the pharmaceutical and healthcare sectors, creation of biological goods, and DNA therapies all contribute to the rise of the nucleic acid therapeutics market. The development of the global nucleic acid therapies market is expected to be constrained by lack of experience, lack of technologies, and their high cost. As both, developed and emerging nations play a significant role in the analysis and development of new therapies, the market is likely to continue to expand in the future. The high cost of research and development, as well as costly therapies and technologies, are some of the key factors limiting industry expansion. Additional factors that are boosting the market expansion for nucleic acid therapeutics globally include, speedier absorption and quicker market access, strong product demand, and a greater concentration of pharmaceutical companies on the development of treatments for nucleic acid therapeutics. The factors that are anticipated to impede the growth of the global nucleic acid therapeutics market during the forecast period include, absence of alternative treatments for a variety of chronic conditions, accessibility of medicines, and high diagnostic costs. The growth of the nucleic acid therapeutics market is driven by increased research & development of new medicines and therapies and increased disease prevalence.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

Market Dynamics

Market Drivers

• Advancements in Gene Editing Technologies:Gene editing technologies have revolutionized the field of nucleic acid-based therapies. CRISPR-Cas9, a prominent example, allows for precise and efficient modification of DNA sequences. This technology has been used to correct genetic mutations, silence harmful genes, and even introduce beneficial genetic changes. Other advancements include TALENs (Transcription Activator-Like Effector Nucleases) and ZFNs (Zinc Finger Nucleases), which also enable targeted gene editing. These tools have expanded the scope of treatable diseases, including rare genetic disorders, cancer, and infectious diseases. Ongoing research aims to improve the specificity and safety of these technologies, further enhancing their therapeutic potential.
• Growing Prevalence of Genetic Disorders:The increasing prevalence of genetic disorders is driving the demand for nucleic acid-based therapies. Conditions such as cystic fibrosis, Huntington's disease, and various types of cancer are linked to specific genetic mutations. Traditional treatments often focus on symptom management rather than addressing the underlying genetic cause. Nucleic acid-based therapies offer a targeted approach to correct or compensate for these genetic abnormalities. As diagnostic technologies improve, more genetic disorders are being identified, leading to a growing need for effective and personalized treatments. This trend is supported by increasing awareness and advocacy for genetic testing and therapy.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Market Challenges

• Regulatory Hurdles and Safety Concerns:The development and approval of nucleic acid-based therapies face significant regulatory challenges. Ensuring the safety and efficacy of these therapies requires extensive preclinical and clinical testing. Regulatory bodies, such as the FDA and EMA, have stringent guidelines to address potential risks, including off-target effects, immune responses, and long-term safety. The complexity of these therapies necessitates robust data to demonstrate their benefits and minimize risks. Additionally, ethical considerations, such as the potential for germline editing, add another layer of regulatory scrutiny. Overcoming these hurdles requires close collaboration between researchers, regulators, and industry stakeholders.
• High Cost of Therapies:Nucleic acid-based therapies are often associated with high costs due to the complex nature of their development, manufacturing, and administration. The research and development process is resource-intensive, involving advanced technologies and extensive clinical trials. Manufacturing these therapies requires specialized facilities and expertise, further adding to the cost. The high price tags of these therapies can limit their accessibility, particularly in regions with constrained healthcare budgets. Addressing the cost issue is crucial for broader adoption and may involve innovative pricing models, such as outcome-based reimbursement, to ensure affordability and sustainability.

Market Trends

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

• Increasing Collaborations and Partnerships:Collaborations and partnerships are becoming increasingly important in the nucleic acid-based therapy market. Pharmaceutical companies, biotech firms, and academic institutions are forming strategic alliances to share resources, expertise, and technologies. These collaborations accelerate the development of new therapies by leveraging complementary strengths. For example, biotech companies may have innovative technologies, while pharmaceutical companies provide the resources and expertise needed for clinical development and commercialization. Such partnerships also facilitate the sharing of risks and costs, making the development process more efficient and effective.
• Emergence of mRNA Vaccines:The emergence of mRNA vaccines has significantly boosted the nucleic acid-based therapy market. mRNA vaccines, such as those developed for COVID-19, have demonstrated rapid development timelines, scalability, and the ability to target a wide range of diseases. These vaccines work by delivering mRNA instructions to cells, which then produce the desired protein to trigger an immune response. The success of mRNA vaccines has highlighted the potential of nucleic acid-based therapies for various applications, including infectious diseases, cancer, and rare genetic disorders. This trend is expected to drive further innovation and investment in mRNA technologies, expanding the therapeutic landscape.

Segmentation Analysis

Based on the report, the Type is segmented into Antisense Oligonucleotides (ASO), siRNA, mRNA

Antisense oligonucleotides (ASOs) are synthetic, single-stranded nucleic acids designed to bind complementary RNA sequences, thereby inhibiting gene expression through various mechanisms, including RNase H-mediated degradation and splicing modulation. They have shown considerable promise in treating genetic disorders and have been approved for several conditions, although challenges such as stability, delivery efficiency, and potential off-target effects remain significant hurdles in their clinical application. siRNA, on the other hand, consists of double-stranded RNA that induces gene silencing via the RNA-induced silencing complex (RISC), leading to the degradation of target mRNA. This approach is particularly effective for transiently knocking down gene expression and has been successfully utilized in clinical trials. However, like ASOs, siRNA faces challenges in delivery and stability, necessitating advanced delivery systems such as lipid nanoparticles. mRNA therapies represent a newer frontier, leveraging the body's own cellular machinery to produce therapeutic proteins. This approach gained prominence during the COVID-19 pandemic, showcasing the potential for rapid development and deployment. mRNA therapies can be designed to encode for proteins that may correct or compensate for disease-related deficiencies, offering a versatile platform for treatment.

Based on the report, the Application is segmented into Neuromuscular Diseases, hATTR, COVID-19

Neuromuscular Diseases segment is significant due to the prevalence of conditions like Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). Therapies utilizing antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) have shown remarkable efficacy. For instance, ASOs like nusinersen have dramatically improved the quality of life and motor function in SMA patients. Additionally, recent approvals for drugs targeting DMD, such as golodirsen and viltolarsen, highlight the potential of these therapies in addressing previously untreatable conditions, with ongoing research expanding into other neuromuscular disorders like amyotrophic lateral sclerosis (ALS) and myotonic dystrophy. Hereditary transthyretin amyloidosis is another critical application area. Treatments like patisiran and inotersen have been developed to silence the TTR gene, effectively reducing amyloid deposits and improving patient outcomes. These therapies represent a shift towards precision medicine, targeting the underlying genetic causes of the disease. The pandemic accelerated the development of mRNA therapies, exemplified by the rapid deployment of vaccines utilizing this technology. These vaccines have proven effective in generating immune responses against the virus, showcasing the versatility of nucleic acid-based therapies in infectious diseases.
Regional Analysis

North America's leadership in the nucleic acid-based therapy market is primarily driven by its robust research and development infrastructure and substantial investment from both public and private sectors. The Asia Pacific region is experiencing rapid growth due to increasing healthcare expenditure, a large patient population, and government initiatives aimed at promoting biotechnology innovation.

North America, particularly the United States, is at the forefront of the nucleic acid-based therapy market due to its well-established research and development ecosystem. The region is home to numerous leading biotechnology and pharmaceutical companies, as well as prestigious academic institutions, which are actively engaged in cutting-edge research. Significant investment from both government agencies, such as the National Institutes of Health (NIH), and private venture capital firms has fueled innovation in this field. Additionally, the presence of advanced healthcare infrastructure and a supportive regulatory environment, with the U.S. Food and Drug Administration (FDA) playing a pivotal role, has facilitated the rapid development and approval of new therapies. The region's strong intellectual property protection laws further encourage innovation and investment. These factors collectively contribute to North America's dominant position in the global nucleic acid-based therapy market. The Asia Pacific region is emerging as a significant player in the nucleic acid-based therapy market, driven by several key factors. The region is characterized by a large and growing patient population, particularly in countries like China and India, which creates a substantial demand for innovative therapies. Increasing healthcare expenditure and improving healthcare infrastructure are enabling better access to advanced treatments. Governments in the region are actively promoting biotechnology innovation through supportive policies, funding, and the establishment of research institutions. For example, China's "Made in China 2025" initiative includes a focus on biotechnology, while India's "Make in India" campaign aims to boost domestic manufacturing of pharmaceuticals. Additionally, the region is attracting significant investment from global pharmaceutical companies seeking to tap into its vast market potential. These factors, combined with a growing awareness of genetic disorders and the need for personalized treatments, are driving the growth of the nucleic acid-based therapy market in the Asia Pacific region.

Key Developments

• In March 2023, Ionis Pharmaceutical received a unanimous vote from the Food and Drug Administration (FDA) advisory committee for the potential accelerated approval of Tofersen for SOD1-ALS. Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis.
• In February 2023, Myeloid Therapeutics Inc. collaborated with New South Wales (NSW) Government in Australia to develop a state-of-the-art GMP manufacturing facility focused on RNA immunotherapies. The new facility would accelerate the commercialization of Myceloid's RNA therapeutics and the construction of an RNA ecosystem in the NSW.

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nucleic Acid-based Therapy Market Size 2019-2030
2.1.2 Nucleic Acid-based Therapy Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Nucleic Acid-based Therapy by Country/Region, 2019, 2023 & 2030
2.2 Nucleic Acid-based Therapy Segment by Type
2.2.1 Antisense Oligonucleotides (ASO)
2.2.2 siRNA
2.2.3 mRNA
2.3 Nucleic Acid-based Therapy Market Size by Type
2.3.1 Nucleic Acid-based Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Nucleic Acid-based Therapy Market Size Market Share by Type (2019-2024)
2.4 Nucleic Acid-based Therapy Segment by Application
2.4.1 Neuromuscular Diseases
2.4.2 hATTR
2.4.3 COVID-19
2.4.4 Other
2.5 Nucleic Acid-based Therapy Market Size by Application
2.5.1 Nucleic Acid-based Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Nucleic Acid-based Therapy Market Size Market Share by Application (2019-2024)
3 Nucleic Acid-based Therapy Market Size by Player
3.1 Nucleic Acid-based Therapy Market Size Market Share by Player
3.1.1 Global Nucleic Acid-based Therapy Revenue by Player (2019-2024)
3.1.2 Global Nucleic Acid-based Therapy Revenue Market Share by Player (2019-2024)
3.2 Global Nucleic Acid-based Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Nucleic Acid-based Therapy by Region
4.1 Nucleic Acid-based Therapy Market Size by Region (2019-2024)
4.2 Global Nucleic Acid-based Therapy Annual Revenue by Country/Region (2019-2024)
4.3 Americas Nucleic Acid-based Therapy Market Size Growth (2019-2024)
4.4 APAC Nucleic Acid-based Therapy Market Size Growth (2019-2024)
4.5 Europe Nucleic Acid-based Therapy Market Size Growth (2019-2024)
4.6 Middle East & Africa Nucleic Acid-based Therapy Market Size Growth (2019-2024)
5 Americas
5.1 Americas Nucleic Acid-based Therapy Market Size by Country (2019-2024)
5.2 Americas Nucleic Acid-based Therapy Market Size by Type (2019-2024)
5.3 Americas Nucleic Acid-based Therapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nucleic Acid-based Therapy Market Size by Region (2019-2024)
6.2 APAC Nucleic Acid-based Therapy Market Size by Type (2019-2024)
6.3 APAC Nucleic Acid-based Therapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Nucleic Acid-based Therapy Market Size by Country (2019-2024)
7.2 Europe Nucleic Acid-based Therapy Market Size by Type (2019-2024)
7.3 Europe Nucleic Acid-based Therapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nucleic Acid-based Therapy by Region (2019-2024)
8.2 Middle East & Africa Nucleic Acid-based Therapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Nucleic Acid-based Therapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Nucleic Acid-based Therapy Market Forecast
10.1 Global Nucleic Acid-based Therapy Forecast by Region (2025-2030)
10.1.1 Global Nucleic Acid-based Therapy Forecast by Region (2025-2030)
10.1.2 Americas Nucleic Acid-based Therapy Forecast
10.1.3 APAC Nucleic Acid-based Therapy Forecast
10.1.4 Europe Nucleic Acid-based Therapy Forecast
10.1.5 Middle East & Africa Nucleic Acid-based Therapy Forecast
10.2 Americas Nucleic Acid-based Therapy Forecast by Country (2025-2030)
10.2.1 United States Market Nucleic Acid-based Therapy Forecast
10.2.2 Canada Market Nucleic Acid-based Therapy Forecast
10.2.3 Mexico Market Nucleic Acid-based Therapy Forecast
10.2.4 Brazil Market Nucleic Acid-based Therapy Forecast
10.3 APAC Nucleic Acid-based Therapy Forecast by Region (2025-2030)
10.3.1 China Nucleic Acid-based Therapy Market Forecast
10.3.2 Japan Market Nucleic Acid-based Therapy Forecast
10.3.3 Korea Market Nucleic Acid-based Therapy Forecast
10.3.4 Southeast Asia Market Nucleic Acid-based Therapy Forecast
10.3.5 India Market Nucleic Acid-based Therapy Forecast
10.3.6 Australia Market Nucleic Acid-based Therapy Forecast
10.4 Europe Nucleic Acid-based Therapy Forecast by Country (2025-2030)
10.4.1 Germany Market Nucleic Acid-based Therapy Forecast
10.4.2 France Market Nucleic Acid-based Therapy Forecast
10.4.3 UK Market Nucleic Acid-based Therapy Forecast
10.4.4 Italy Market Nucleic Acid-based Therapy Forecast
10.4.5 Russia Market Nucleic Acid-based Therapy Forecast
10.5 Middle East & Africa Nucleic Acid-based Therapy Forecast by Region (2025-2030)
10.5.1 Egypt Market Nucleic Acid-based Therapy Forecast
10.5.2 South Africa Market Nucleic Acid-based Therapy Forecast
10.5.3 Israel Market Nucleic Acid-based Therapy Forecast
10.5.4 Turkey Market Nucleic Acid-based Therapy Forecast
10.6 Global Nucleic Acid-based Therapy Forecast by Type (2025-2030)
10.7 Global Nucleic Acid-based Therapy Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Nucleic Acid-based Therapy Forecast
11 Key Players Analysis
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics Nucleic Acid-based Therapy Product Offered
11.1.3 Sarepta Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Information
11.2.2 Ionis Pharmaceuticals Nucleic Acid-based Therapy Product Offered
11.2.3 Ionis Pharmaceuticals Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Ionis Pharmaceuticals Main Business Overview
11.2.5 Ionis Pharmaceuticals Latest Developments
11.3 Alnylam
11.3.1 Alnylam Company Information
11.3.2 Alnylam Nucleic Acid-based Therapy Product Offered
11.3.3 Alnylam Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Alnylam Main Business Overview
11.3.5 Alnylam Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen Nucleic Acid-based Therapy Product Offered
11.4.3 Biogen Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Information
11.5.2 Nippon Shinyaku Nucleic Acid-based Therapy Product Offered
11.5.3 Nippon Shinyaku Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Nippon Shinyaku Main Business Overview
11.5.5 Nippon Shinyaku Latest Developments
11.6 Sobi
11.6.1 Sobi Company Information
11.6.2 Sobi Nucleic Acid-based Therapy Product Offered
11.6.3 Sobi Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Sobi Main Business Overview
11.6.5 Sobi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Nucleic Acid-based Therapy Product Offered
11.7.3 Novartis Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 BioNTech
11.8.1 BioNTech Company Information
11.8.2 BioNTech Nucleic Acid-based Therapy Product Offered
11.8.3 BioNTech Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 BioNTech Main Business Overview
11.8.5 BioNTech Latest Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Nucleic Acid-based Therapy Product Offered
11.9.3 Pfizer Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Pfizer Main Business Overview
11.9.5 Pfizer Latest Developments
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Information
11.10.2 Moderna Therapeutics Nucleic Acid-based Therapy Product Offered
11.10.3 Moderna Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Moderna Therapeutics Main Business Overview
11.10.5 Moderna Therapeutics Latest Developments
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Information
11.11.2 Jazz Pharmaceuticals Nucleic Acid-based Therapy Product Offered
11.11.3 Jazz Pharmaceuticals Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Jazz Pharmaceuticals Main Business Overview
11.11.5 Jazz Pharmaceuticals Latest Developments
11.12 CureVac
11.12.1 CureVac Company Information
11.12.2 CureVac Nucleic Acid-based Therapy Product Offered
11.12.3 CureVac Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 CureVac Main Business Overview
11.12.5 CureVac Latest Developments
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Information
11.13.2 Regulus Therapeutics Nucleic Acid-based Therapy Product Offered
11.13.3 Regulus Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Regulus Therapeutics Main Business Overview
11.13.5 Regulus Therapeutics Latest Developments
11.14 ProQR
11.14.1 ProQR Company Information
11.14.2 ProQR Nucleic Acid-based Therapy Product Offered
11.14.3 ProQR Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 ProQR Main Business Overview
11.14.5 ProQR Latest Developments
11.15 Secarna
11.15.1 Secarna Company Information
11.15.2 Secarna Nucleic Acid-based Therapy Product Offered
11.15.3 Secarna Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Secarna Main Business Overview
11.15.5 Secarna Latest Developments
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Information
11.16.2 MiNA Therapeutics Nucleic Acid-based Therapy Product Offered
11.16.3 MiNA Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 MiNA Therapeutics Main Business Overview
11.16.5 MiNA Therapeutics Latest Developments
11.17 Sylentis
11.17.1 Sylentis Company Information
11.17.2 Sylentis Nucleic Acid-based Therapy Product Offered
11.17.3 Sylentis Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Sylentis Main Business Overview
11.17.5 Sylentis Latest Developments
11.18 Arrowhead
11.18.1 Arrowhead Company Information
11.18.2 Arrowhead Nucleic Acid-based Therapy Product Offered
11.18.3 Arrowhead Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Arrowhead Main Business Overview
11.18.5 Arrowhead Latest Developments
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Information
11.19.2 Silence Therapeutics Nucleic Acid-based Therapy Product Offered
11.19.3 Silence Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Silence Therapeutics Main Business Overview
11.19.5 Silence Therapeutics Latest Developments
11.20 Dicerna
11.20.1 Dicerna Company Information
11.20.2 Dicerna Nucleic Acid-based Therapy Product Offered
11.20.3 Dicerna Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Dicerna Main Business Overview
11.20.5 Dicerna Latest Developments
12 Research Findings and Conclusion

List of Tables
Table 1. Nucleic Acid-based Therapy Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Nucleic Acid-based Therapy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Nucleic Acid-based Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 7. Global Nucleic Acid-based Therapy Market Size by Type (2019-2024) & ($ millions)
Table 8. Global Nucleic Acid-based Therapy Market Size Market Share by Type (2019-2024)
Table 9. Nucleic Acid-based Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 10. Global Nucleic Acid-based Therapy Market Size by Application (2019-2024) & ($ millions)
Table 11. Global Nucleic Acid-based Therapy Market Size Market Share by Application (2019-2024)
Table 12. Global Nucleic Acid-based Therapy Revenue by Player (2019-2024) & ($ millions)
Table 13. Global Nucleic Acid-based Therapy Revenue Market Share by Player (2019-2024)
Table 14. Nucleic Acid-based Therapy Key Players Head office and Products Offered
Table 15. Nucleic Acid-based Therapy Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Nucleic Acid-based Therapy Market Size by Region (2019-2024) & ($ millions)
Table 19. Global Nucleic Acid-based Therapy Market Size Market Share by Region (2019-2024)
Table 20. Global Nucleic Acid-based Therapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Nucleic Acid-based Therapy Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Nucleic Acid-based Therapy Market Size by Country (2019-2024) & ($ millions)
Table 23. Americas Nucleic Acid-based Therapy Market Size Market Share by Country (2019-2024)
Table 24. Americas Nucleic Acid-based Therapy Market Size by Type (2019-2024) & ($ millions)
Table 25. Americas Nucleic Acid-based Therapy Market Size Market Share by Type (2019-2024)
Table 26. Americas Nucleic Acid-based Therapy Market Size by Application (2019-2024) & ($ millions)
Table 27. Americas Nucleic Acid-based Therapy Market Size Market Share by Application (2019-2024)
Table 28. APAC Nucleic Acid-based Therapy Market Size by Region (2019-2024) & ($ millions)
Table 29. APAC Nucleic Acid-based Therapy Market Size Market Share by Region (2019-2024)
Table 30. APAC Nucleic Acid-based Therapy Market Size by Type (2019-2024) & ($ millions)
Table 31. APAC Nucleic Acid-based Therapy Market Size by Application (2019-2024) & ($ millions)
Table 32. Europe Nucleic Acid-based Therapy Market Size by Country (2019-2024) & ($ millions)
Table 33. Europe Nucleic Acid-based Therapy Market Size Market Share by Country (2019-2024)
Table 34. Europe Nucleic Acid-based Therapy Market Size by Type (2019-2024) & ($ millions)
Table 35. Europe Nucleic Acid-based Therapy Market Size by Application (2019-2024) & ($ millions)
Table 36. Middle East & Africa Nucleic Acid-based Therapy Market Size by Region (2019-2024) & ($ millions)
Table 37. Middle East & Africa Nucleic Acid-based Therapy Market Size by Type (2019-2024) & ($ millions)
Table 38. Middle East & Africa Nucleic Acid-based Therapy Market Size by Application (2019-2024) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Nucleic Acid-based Therapy
Table 40. Key Market Challenges & Risks of Nucleic Acid-based Therapy
Table 41. Key Industry Trends of Nucleic Acid-based Therapy
Table 42. Global Nucleic Acid-based Therapy Market Size Forecast by Region (2025-2030) & ($ millions)
Table 43. Global Nucleic Acid-based Therapy Market Size Market Share Forecast by Region (2025-2030)
Table 44. Global Nucleic Acid-based Therapy Market Size Forecast by Type (2025-2030) & ($ millions)
Table 45. Global Nucleic Acid-based Therapy Market Size Forecast by Application (2025-2030) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 47. Sarepta Therapeutics Nucleic Acid-based Therapy Product Offered
Table 48. Sarepta Therapeutics Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Nucleic Acid-based Therapy Product Offered
Table 53. Ionis Pharmaceuticals Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 57. Alnylam Nucleic Acid-based Therapy Product Offered
Table 58. Alnylam Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 62. Biogen Nucleic Acid-based Therapy Product Offered
Table 63. Biogen Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 67. Nippon Shinyaku Nucleic Acid-based Therapy Product Offered
Table 68. Nippon Shinyaku Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 72. Sobi Nucleic Acid-based Therapy Product Offered
Table 73. Sobi Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 77. Novartis Nucleic Acid-based Therapy Product Offered
Table 78. Novartis Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 82. BioNTech Nucleic Acid-based Therapy Product Offered
Table 83. BioNTech Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 87. Pfizer Nucleic Acid-based Therapy Product Offered
Table 88. Pfizer Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 92. Moderna Therapeutics Nucleic Acid-based Therapy Product Offered
Table 93. Moderna Therapeutics Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Nucleic Acid-based Therapy Product Offered
Table 98. Jazz Pharmaceuticals Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 102. CureVac Nucleic Acid-based Therapy Product Offered
Table 103. CureVac Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 107. Regulus Therapeutics Nucleic Acid-based Therapy Product Offered
Table 108. Regulus Therapeutics Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 112. ProQR Nucleic Acid-based Therapy Product Offered
Table 113. ProQR Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 117. Secarna Nucleic Acid-based Therapy Product Offered
Table 118. Secarna Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 122. MiNA Therapeutics Nucleic Acid-based Therapy Product Offered
Table 123. MiNA Therapeutics Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 127. Sylentis Nucleic Acid-based Therapy Product Offered
Table 128. Sylentis Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 132. Arrowhead Nucleic Acid-based Therapy Product Offered
Table 133. Arrowhead Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 137. Silence Therapeutics Nucleic Acid-based Therapy Product Offered
Table 138. Silence Therapeutics Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Nucleic Acid-based Therapy Area Served and Its Competitors
Table 142. Dicerna Nucleic Acid-based Therapy Product Offered
Table 143. Dicerna Nucleic Acid-based Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments

List of Figures
Figure 1. Nucleic Acid-based Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Nucleic Acid-based Therapy Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Nucleic Acid-based Therapy Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Nucleic Acid-based Therapy Sales Market Share by Country/Region (2023)
Figure 8. Nucleic Acid-based Therapy Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Nucleic Acid-based Therapy Market Size Market Share by Type in 2023
Figure 10. Nucleic Acid-based Therapy in Neuromuscular Diseases
Figure 11. Global Nucleic Acid-based Therapy Market: Neuromuscular Diseases (2019-2024) & ($ millions)
Figure 12. Nucleic Acid-based Therapy in hATTR
Figure 13. Global Nucleic Acid-based Therapy Market: hATTR (2019-2024) & ($ millions)
Figure 14. Nucleic Acid-based Therapy in COVID-19
Figure 15. Global Nucleic Acid-based Therapy Market: COVID-19 (2019-2024) & ($ millions)
Figure 16. Nucleic Acid-based Therapy in Other
Figure 17. Global Nucleic Acid-based Therapy Market: Other (2019-2024) & ($ millions)
Figure 18. Global Nucleic Acid-based Therapy Market Size Market Share by Application in 2023
Figure 19. Global Nucleic Acid-based Therapy Revenue Market Share by Player in 2023
Figure 20. Global Nucleic Acid-based Therapy Market Size Market Share by Region (2019-2024)
Figure 21. Americas Nucleic Acid-based Therapy Market Size 2019-2024 ($ millions)
Figure 22. APAC Nucleic Acid-based Therapy Market Size 2019-2024 ($ millions)
Figure 23. Europe Nucleic Acid-based Therapy Market Size 2019-2024 ($ millions)
Figure 24. Middle East & Africa Nucleic Acid-based Therapy Market Size 2019-2024 ($ millions)
Figure 25. Americas Nucleic Acid-based Therapy Value Market Share by Country in 2023
Figure 26. United States Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 27. Canada Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 28. Mexico Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 29. Brazil Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 30. APAC Nucleic Acid-based Therapy Market Size Market Share by Region in 2023
Figure 31. APAC Nucleic Acid-based Therapy Market Size Market Share by Type (2019-2024)
Figure 32. APAC Nucleic Acid-based Therapy Market Size Market Share by Application (2019-2024)
Figure 33. China Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 34. Japan Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 35. South Korea Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 36. Southeast Asia Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 37. India Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 38. Australia Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 39. Europe Nucleic Acid-based Therapy Market Size Market Share by Country in 2023
Figure 40. Europe Nucleic Acid-based Therapy Market Size Market Share by Type (2019-2024)
Figure 41. Europe Nucleic Acid-based Therapy Market Size Market Share by Application (2019-2024)
Figure 42. Germany Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 43. France Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 44. UK Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 45. Italy Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 46. Russia Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 47. Middle East & Africa Nucleic Acid-based Therapy Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Nucleic Acid-based Therapy Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Nucleic Acid-based Therapy Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 51. South Africa Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 52. Israel Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 53. Turkey Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 54. GCC Countries Nucleic Acid-based Therapy Market Size Growth 2019-2024 ($ millions)
Figure 55. Americas Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 56. APAC Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 57. Europe Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 58. Middle East & Africa Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 59. United States Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 60. Canada Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 61. Mexico Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 62. Brazil Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 63. China Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 64. Japan Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 65. Korea Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 66. Southeast Asia Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 67. India Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 68. Australia Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 69. Germany Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 70. France Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 71. UK Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 72. Italy Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 73. Russia Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 74. Egypt Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 75. South Africa Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 76. Israel Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 77. Turkey Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 78. GCC Countries Nucleic Acid-based Therapy Market Size 2025-2030 ($ millions)
Figure 79. Global Nucleic Acid-based Therapy Market Size Market Share Forecast by Type (2025-2030)
Figure 80. Global Nucleic Acid-based Therapy Market Size Market Share Forecast by Application (2025-2030)
"

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted